Dr Sarah Howell, chief executive of , speaks to Proactive London after announcing the dosing of the first patient in a Phase I clinical trial for its ultra-rapid acting insulin product candidate AT247.
AT247 is an ultra-rapid acting product candidate targeting improved treatment for people living with Type I diabetes.
The trial is being carried out in Austria with preliminary results expected towards the end of the year.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...
FOR OUR FULL DISCLAIMER CLICK HERE